Halozyme Therapeutics Profit Margin 2006-2021 | HALO
Current and historical gross margin, operating margin and net profit margin for Halozyme Therapeutics (HALO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Halozyme Therapeutics net profit margin as of June 30, 2021 is 55.45%.
|Halozyme Therapeutics Annual Profit Margins
|Halozyme Therapeutics Quarterly Profit Margins
||Medical - Biomedical and Genetics
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.